Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its mature…
rtfolio. Revenue totaled JPY 1.22 trillion, up 10.2% on an actual foreign-exchange basis but down 0.5% at constant exchange rates, according to Chief Financial Officer Milano Furuta
Core operating profit was JPY 358.9 billion, rising 11.5% on an actual FX basis and declining 0.5% at constant exchange rates. Reported operating profit was JPY 201.4 billion. – Time to buy these 3 healthcare companies that raised revenue guidance? Core earnings per share were JPY 154, down 11.8% at constant exchange rates, primarily reflecting a favorable tax position in the prior year.
Reported EPS was JPY 72. The company left its fiscal 2026 guidance unchanged and said it remains on track to generate JPY 650 billion to JPY 750 billion in free cash flow for the year. Core brands and new launches offset portfolio pressure Core inline brands, which represented 58% of total revenue, grew 2.3% at constant exchange rates.